Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

TRAIL-R2 (human):Fc (human), (recombinant)

 
ALX-522-005-C050 50 µg 402.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:DR5, TNFRSF 10B, KILLER, CD262
 
MW:58kDa (SDS-PAGE).
 
Source:Produced in HEK 293 cells. The extracellular domain of human TRAIL-R2 (DR5) (aa 52-212) is fused to the Fc portion of human IgG1.
 
UniProt ID:O14763
 
Concentration:1mg/ml after reconstitution.
 
Formulation:Lyophilized. Contains PBS.
 
Purity:≥95% (SDS-PAGE)
 
Endotoxin Content:<0.1EU/µg purified protein (LAL test; Bio Whittaker).
 
Species reactivity:Human, Mouse
 
Specificity:Binds human and mouse TRAIL.
 
Biological Activity:Inhibits human soluble TRAIL-mediated apoptosis.
 
Applications:ELISA
 
Application Notes:ELISA: binds to TRAIL at 10-100 ng/ml.
 
Reconstitution:Reconstitute with 50µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum or a carrier protein.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C.
 
Handling:Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
 
Technical Info/Product Notes:Historical data has shown inhibition of human soluble TRAIL-induced apoptosis in a concentration range of 0.5-10µg/ml.
 
ALX-522-005 SDS-PAGE
Fig 1: SDS-PAGE Analysis. Lane 1: MW Marker, Lane 2: 1 µg, Lane 3: 2 µg TRAIL-R2.
ALX-522-005 ELISA
Fig 2: ELISA Analysis: 100 ng/well of receptor or control is coated on a 96-well plate. After blocking, ligand is titrated 2-fold in series, and detected with anti-flag antibody. TRAIL (Prod # ALX-522-003) shows positive for binding to TRAIL-R2 and negative for binding to either Fc control protein (Prod # ALX-203-004) and buffer control.
Please mouse over
ALX-522-005 SDS-PAGE ALX-522-005 ELISA

Product Literature References

Serine 574 phosphorylation alters transcriptional programming of FOXO3 by selectively enhancing apoptotic gene expression: Z. Li, et al.; Cell Death Differ. 23, 583 (2016), Abstract;
Death receptor 5 signaling promotes hepatocyte lipoapoptosis: S.C. Cazanave, et al.; J. Biol. Chem. 286, 39336 (2011), Abstract;
Proteasome inhibition can induce an autophagy-dependent apical activation of caspase-8: M.A. Laussmann, et al.; Cell Death Differ. 18, 1584 (2011), Abstract;
Two adjacent trimeric fas ligands are required for fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003), Abstract; Full Text
Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells: J.D. Lunemann, et al.; J. Immunol. 168, 4881 (2002), Abstract; Full Text
Induction of TRAIL-mediated glioma cell death by human T cells: J. Dörr, et al.; J. Neuroimmunol. 122, 117 (2002), Abstract;
Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand: G. Lu, et al.; J. Immunol. 168, 1831 (2002), Abstract; Full Text
Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Signaling in Activated T Cells Abrogates TRAIL-Induced Apoptosis Upstream of the Mitochondrial Amplification Loop and Caspase-8: T.S. Soderstrom, et al.; J. Immunol. 169, 2851 (2002), Abstract;
T cells require TRAIL for optimal graft-versus-tumor activity: C. Schmaltz, et al.; Nat. Med. 8, 1433 (2002), Abstract;
TRAIL/Apo-2 ligand induces primary plasma cell apoptosis: J. Ursini-Siegel, et al.; J. Immunol. 169, 5505 (2002), Abstract; Full Text
Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors: N. Holler, et al.; J. Immunol. Methods 237, 159 (2000), Abstract;
The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation: F. Mühlenbeck, et al.; J. Biol. Chem. 275, 32208 (2000), Abstract; Full Text

Related Products

Control:Fc fusion protein (human), (recombinant) 

Negative control for Fc chimeric proteins
Produced in HEK 293 cells. The extracellular domain of mutated hThy-1, hThy-1 (RLE) (aa 20-130), is fused to the Fc portion of human IgG1. The integrin binding sequence RLD of hThy-1 has been changed to RLE abolishing the binding of integrins., ≥90% (SDS-PAGE) | Print as PDF
 
ALX-203-004-C050 50 µg 405.00 USD
Do you need bulk/larger quantities?
 

TRAIL, soluble (human) (recombinant) set 

Produced in E. coli. The extracellular domain of human TRAIL (Apo-2L) (aa 95-281) is fused at the N-terminus to a linker peptide (8 aa) and a FLAG®-tag., ≥95% (SDS-PAGE), FUNC | Print as PDF
 
ALX-850-018-KI01 1 Set 561.00 USD
Do you need bulk/larger quantities?
 

TRAIL-R2 (human):Fc (human), (recombinant) (FITC conjugate) 

Produced in HEK 293 cells. The extracellular domain of human TRAIL-R2 (DR5) (aa 52-212) is fused to the Fc portion of human IgG1., ≥95% (SDS-PAGE), Flow Cytometry | Print as PDF
 
ALX-522-005F-C050 50 µg FITC 399.00 USD
Do you need bulk/larger quantities?
 

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
TRAIL receptor
By biological activity:
TRAIL receptor Recombinant protein
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Product Flyers
TRAIL & TRAIL Receptors
TRAIL & TRAIL Receptors
Download as PDF

All new literature pieces

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,